EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
NAFLD SUMMIT 201926-28 September 2019 Seville
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P06-01 | miR-34a is strongly activated in human and experimental NAFLD, correlating with key disease hallmarks | André Simão |  Received |
 |
|||
| P03-01 | Obese patients carrying NAFLD-associated genetic variants present specific serum and liver lipidomic profiles: identification of a lipidomic signature in serum to estimate the liver fat content. | Pedro Miguel Rodrigues | Received |
|
|||
| P04-01 | A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors | Anna Mantovani | Received |
|
|||
| P02-01 | Berberis Aristata, Elaeis Guineensis and Coffea Canephora extracts modulate the Insulin Receptor expression and improve hepatic steatosis in NAFLD patients: a pilot study | Valentina Cossiga | Received |
|
|||
| P01-01 | Pilot study of liraglutide on weight and enzymes of obese patients with NAFLD | Amr Asem Elfert | Received |
|
|||
| P05-01 | Alcohol and other contributing factors to the burden of liver disease among patients with type-2 diabetes mellitus: a retrospective longitudinal study | Lucia PARLATI | Received |
|
|||
| P01-02 | RIP3-dependent signalling impacts on lipid metabolism and halts disease progression in experimental non-alcoholic fatty liver disease | Marta B. Afonso | Received |
|
|||
| P04-02 | Risk factors in type 2 diabetic mellitus patients | Ruxandra-Georgeta Mare | Received |
|
|||
| P06-02 | Regulation of magnesium homeostasis through CNNM4 modulation resolves NAFLD | Jorge Simón | Received |
|
|||
| P05-02 | Changes in individual free fatty acids during an oral glucose tolerance test in non-alcoholic fatty liver disease subjects stratified by body mass index | Bárbara Patrício | Received |
|
|||
| P02-02 | The economic burden of patients diagnosed with non-alcoholic steatohepatitis in France, Germany, Italy, Spain and the United Kingdom in 2018 | Sandrine Cure | Received |
|
|||
| P03-03 | Estimated GFR is associated with PNPLA3 risk variant p.I148M in patients with non-alcoholic fatty liver disease | Marcin Krawczyk | Received |
|
|||
| P06-03 | Serum adenosine deaminase values are associated with advanced liver disease in patients with Non-Alcoholic Fatty Liver Disease | Emmanouil Sinakos | Received |
|
|||
| P01-03 | Co-creating Comics to Communicate Non-Alcoholic Fatty Liver Disease - A participatory Research Approach | Mireia Alemany i Pagès | Received |
|
|||
| P05-03 | Early immunological modifications of the intestinal barrier in response to a non-alcoholic steatohepatitis-inducing diet | Simon Peschard | Received |
|
|||
| P04-03 | Psoriasis and liver damage in HIV-infected subjects | M Luisa Montes Ramírez | Received |
|
|||
| P02-03 | Cardiovascular risk assessment in a non-alcoholic fatty liver disease group of romanian patients | Dascalu Daciana Nicoleta | Received |
|
|||
| P03-04 | Cannabis consumption prevents hepatic steatosis in psychosis patients | PAULA IRUZUBIETA | Received |
|
|||
| P01-04 | Decreased expressions of p70S6K in NK cells of NAFLD patients inhibited F-actin and was correlated with their impaired function | Johnny Amer | Received |
|
|||
| P05-04 | The efficacy of L-carnitine administration in nonalcoholic fatty liver disease patients | Vasyl Prysyazhnyuk | Received |
|
|||
| P04-04 | Predictive circulating hormone biomarkers for NAFLD patient stratification | Vanda Marques | Received |
|
|||
| P02-04 | Is diabetes mellitus associated with hepatocellular carcinoma in patients with chronic liver disease of non viral etiology?: A case control study | Ravi Daswani | Received |
|
|||
| P06-04 | Diagnostic performance of three non-invasive fibrosis scores (Hepamet, Fib-4, Nafld Score) on NAFLD in a mixed Brazilian population | Claudia Oliveira | Received |
|
|||
| P01-05 | High prevalence of fatty liver in diabetes: comparison between ecographic and biochemical diagnostic methods | Rita Andrade | Received |
|
|||
| P03-05 | Triple targeting of nuclear receptors protects against diet-induced NAFLD in mice | Tawhidul Islam | Received |
|
|||
| P05-05 | A deep learning algorithm to quantify liver fat content in humans | Sami Qadri | Received |
|
|||
| P02-05 | Picroside II protects FFA-induced lipid accumulation and lipotoxicity in an in-vitro model of NAFLD | Hiteshi Dhami-Shah | Received |
|
|||
| P06-05 | Establishment of a 3D human liver model to recapitulate NASH progression in vitro | Simon Stroebel | Received |
|
|||
| P04-05 | Relationship of semiquantitative scoring systems with computered-assisted digital image analysis for quantification of histological features in NAFLD | David Marti-Aguado | Received |
|
|||
| P05-06 | The effect of subclinical hypothyroidism on cardiovascular aging in individuals with non-alcoholic fatty liver disease | Anastasiia Radchenko | Received |
|
|||
| P06-06 | Evaluating accuracy of serum steatosis and fibrosis scores in a cohort of morbid obese patients | Moira Testa | Received |
|
|||
| P02-06 | Liver damage in nonalcoholic fatty liver disease: Changes in stearoyl-CoA-desaturase index and metalloproteinase activity | Laura Giuseppina Di Pasqua | Received |
|
|||
| P01-06 | High risk of non-alcoholic fatty liver disease and significant liver fibrosis in patients with hidradenitis suppurativa | Maria Teresa Arias Loste | Received |
|
|||
| P04-06 | The role of adipocyte-derived extracellular vesicles in the development of NAFLD | Johanna Matilainen | Received |
|
|||
| P03-06 | Mitochondrial DNA Analysis in NASH patients | Maciej Jablkowski | Received |
|
|||
| P02-07 | Effect of obeticholic acid on liver function in patients with fibrosis due to NASH | Alicia Meli | Received |
|
|||
| P04-07 | PNPLA3 gene polymorphism (rs738409) and non-alcoholic fatty liver disease risk in women with polycystic ovary syndrome | Amanda Medeiros Recuero | Received |
|
|||
| P06-07 | Circulating mir-192-5p as a novel biomarker for liver fibrosis progression to cirrhosis | Lisa Tran | Received |
|
|||
| P05-07 | Omitted liver disease screening in acute screening coronary syndrome hides prevalence of high levels of severe liver fibrosis | Rebecca Reynolds | Received |
|
|||
| P01-07 | Hyperferritinemia and long-term outcomes in NAFLD patients. A longitudinal multicenter study. | Angelo Armandi | Received |
|
|||
| P03-07 | High-throughput sequencing identified miR-193a as a potential biomarker of non-alcoholic fatty liver disease activity | Katherine Johnson | Received |
|
|||
| P02-08 | Differential effects of palmitic acid on the development of NASH and related metabolic disorders | Olga Estévez Vázquez | Received |
|
|||
| P03-08 | BTT-105 ameliorates non-alcoholic steatohepatitis on diet induced animal models and attenuated lysophosphoatidic acid induced hepatic stellate cell activation. | Dae Won Jun | Received |
|
|||
| P04-08 | Metagenomics and molecular phenomics of obesity and hepatic steatosis | Stijn Meijnikman | Received |
|
|||
| P01-08 | High fat-high sucrose diet promotes liver disease progression and defective metabolic adaptation | Gerard Baiges | Received |
|
|||
| P06-08 | Non-electrophilic activation of the NRF2 pathway ameliorated experimental Nonalcoholic Steatohepatitis | Carmen Valcarce | Received |
|
|||
| P01-09 | Liver fibrosi but not PNPLA3 mutation is associated with decreased renal function in non-alcoholic fatty liver disease | francesco baratta | Received |
|
|||
| P03-09 | Saroglitazar, a potential treatment for Non-Alcoholic Fatty Liver Disease/ Non-Alcoholic Steatohepatitis: Preliminary evidence from pre-clinical, clinical and real world studies | Manjunath K | Received |
|
|||
| P06-09 | Dietary switch and exercise differentially resolove NASH and fibrosis | Anita M. Van Den Hoek | Received |
|
|||
| P02-09 | Deletion of Keap1 and L-in in mice protects from NAFLD progression | Sreepradha Eswaran | Received |
|
|||
| P05-09 | lncRNA-H19 as an epigenetic biomarker of liver cancer stem cells | Ángela Rojas | Received |
|
|||
| P04-09 | Physical activity removes the harmful effects of sedentary behaviours: a prospective look to the Horizon 2020 Foie Gras project in Southern Italy. | Emilio Molina Molina | Received |
|
|||
| P02-10 | The relationship of systemic inflammation and endothelial dysfunction with blood lipid spectrum and adipokines levels in patients with NAFLD | Iryna Fedzhaga | Received |
|
|||
| P04-10 | miRNAs as non-invasive biomarkers in Non-alcoholic Fatty Liver Disease (NAFLD) | Rocío Montero-Vallejo | Received |
|
|||
| P01-10 | Plasma glycine concentration is inversely associated to hepatic and anabolic insulin resistance in subjects with NAFLD | Chiara Barbieri | Received |
|
|||
| P05-10 | NAFLD population in Northern and Southern Italy. A longitudinal and epidemiological study in four tertiary centers. | Ramy Younes | Received |
|
|||
| P03-10 | Validation of a simple 2 step strategy involving FIB4 and mre in evaluation of non alcoholic fatty liver disease | Swati Kaamble | Received |
|
|||
| P06-10 | Oxidized-LDL as a marker of oxidative stress is strongly related to NASH irrespectively of insulin resistance and liver fibrosis | Rocío Gallego-Durán | Received |
|
|||
| P02-11 | Effect of elafibranor treatment and dietary intervention in the Gubra Amylin NASH (GAN) diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis | Michael Feigh | Received |
|
|||
| P04-11 | Inhibition of alpha 2A adrenergic receptors reduces liver inflammation and fibrosis in experimental NASH | Raj Mookerjee | Received |
|
|||
| P03-11 | Fasting Refeeding HFD Mice Accumulate Hepatic Lipid and Develop Metabolic Dysfunction which Control by NQO1 Enzymatic Action | Dipendra Khadka | Received |
|
|||
| P01-11 | Increased hepatic Angiopoietin-Like Protein 3 is associated with NAFLD and with liver expression of vitamin D receptor and vitamin D hydroxylases | Ilaria Barchetta | Received |
|
|||
| P06-11 | Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment | Axelle Louard | Received |
|
|||
| P05-11 | Differences in anxiety and depressive symptomatology of NAFLD/NASH patients according to fibrosis stage | Jesús Funuyet-Salas | Received |
|
|||
| P06-12 | A high-cholesterol diet promotes steatohepatitis and liver tumorigenesis in HCV core gene transgenic mice | Xiaojing Wang | Received |
|
|||
| P02-12 | Mitochondrial GNMT-complex II interaction is recovered by miR-873-5p targeting in NAFLD | David Fernández Ramos | Received |
|
|||
| P04-12 | Early diagnosis of fibrosis in non - alcoholic fatty liver disease | Saidrakhim Lukmonov | Received |
|
|||
| P01-12 | The role endothelial lipase in patients with non-alcoholic fatty liver disease and hypertension depending on the performance of the lipid profile | Anna Bashkirova | Received |
|
|||
| P05-12 | Nover 3D Human NASH model for high-throughput compatible efficacy testing | Simon Stroebel | Received |
|
|||
| P03-12 | HSD17B13 and PNPLA3 gene variants exert opposite effects on non-alcoholic fatty liver phenotypes: results from the real life FLAG cohort | Marcin Krawczyk | Received |
|
|||
| P06-13 | Changes in autophagic flux in diet-induced non-alcoholic fatty liver disease and hepatic fibrosis models in C57Bl/6 mice. | Christine Yee | Received |
|
|||
| P03-13 | Urea cycle enzymes dysregulation is linked to a more agressive NAFLD phenotype | Rocío Gallego-Durán | Received |
|
|||
| P02-13 | Impact of BMI and Ethnicity on histology as assessed by automated quantitation in liver biopsies of patients with NAFLD | Roberta Forlano | Received |
|
|||
| P01-13 | The genetic background strongly influences the development of steatohepatitis and metabolic syndrome in a novel experimental model of dual ASH/NASH | Raquel Benedé Ubieto | Received |
|
|||
| P04-13 | S-adenosylmethionine alleviates hepatic steatosis via alternation of lipid- and bile acid-metabolism and microbiota | Makoto Nakamuta | Received |
|
|||
| P05-13 | Elevated expressions of Sodium taurocholate co-transporting polypeptide (NTCP) on NK cells impaired their function and contribute to liver fibrosis in NAFLD patients | Ahmed Salhab | Received |
|
|||
| P05-14 | Combined treatment with L-carnitine and nicotinamide riboside improves hepatic metabolism and attenuates obesity, hepatic peroxidation and steatosis | kanita salic | Received |
|
|||
| P06-14 | The smoking-hemoglobin interaction and risk for advanced fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease | Yusuf Yilmaz | Received |
|
|||
| P02-14 | A translational mouse model for NASH and advanced fibrosis in association with atherosclerosis | Anita M. Van Den Hoek | Received |
|
|||
| P01-14 | Selective modulation of mGlu5 receptor affects oleic and palmitic acid-induced steatosis in HepG2 cells | CLARISSA BERARDO | Received |
|
|||
| P04-14 | Moderate alcohol consumption is associated with higher grade of liver fibrosis in patients with non-alcoholic fatty liver disease | Lorenzo Mulazzani | Received |
|
|||
| P03-14 | The features of gut microbiota composition in patients with NAFLD | Khrystyna Kvit | Received |
|
|||
| P06-15 | Ductular Reaction Predicts the Progression of Non-Alcoholic Fatty Liver Disease | Ramy Younes | Received |
|
|||
| P02-15 | Gut microbiota composition in patients with nonalcoholic fatty liver disease | Khrystyna Kvit | Received |
|
|||
| P05-15 | acNASH Index: A Novel Screening Tool For Nonalcoholic Steatohepatitis Patients With Persistent Normal Alanine Aminotransferase | Kenneth Iden Zheng | Received |
|
|||
| P03-15 | Nuclear NFATc1 regulates pro-apoptotic ER stress signaling protein CHOP, and progresses NAFLD to NASH | Muhammad Umair Latif | Received |
|
|||
| P04-15 | circulating pcsk9 levels correlated with advanced disease in patients with biopsy-proven non alcoholic fatty liver disease | Rocío Muñoz Hernández | Received |
|
|||
| P01-15 | Liraglutide improves NASH and metabolic disorders in a 3-week diet-induced NASH mouse model | Francois Briand | Received |
|
|||
| P06-16 | Coping strategies and fibrosis: a psychological approach to NAFLD | Jesús Funuyet-Salas | Received |
|
|||
| P02-16 | Propionic acid intervention in obese Ldlr-/-.Leiden mice attenuates NASH development, but negatively affects cognition | Eveline Gart | Received |
|
|||
| P04-16 | The co-stimulatory signals mediated by icos-icosl dyad promote the evolution of non-alcoholic steatohepatitis (nash) | Naresh Naik Ramavath | Received |
|
|||
| P01-16 | Genes involved in the bile acid transport and metabolism and their contribution to disease predisposition in a cohort of children with biopsy-proven NAFLD | Teresa Brunetti | Received |
|
|||
| P05-16 | PNPLA3 could help the clinicians to individuate NAFLD subjects at major risk of disease progression: a single center cohort study | Antonio Salvati | Received |
|
|||
| P03-17 | Function of PX as a novel NOX4 regulator in nonalcoholic steatohepatitis | Hye-Eun Lee | Received |
|
|||
| P06-17 | Network-based drug-repositioning platform identifies pharmacological compounds with anti-steatogenic mode of action | Danae Zareifi | Received |
|
|||
| P05-17 | IDL-2965: A ive, highly potent, clinical stage integrin antagonist for the treatment of NASH | Scott Seiwert | Received |
|
|||
| P02-17 | Comparing computerized tomography indices and liver biopsy in liver transplantation donors for hepatosteatosis | Genco Gencdal | Received |
|
|||
| P01-17 | Targeting liver Glutaminase 1 ameliorates NASH by restoring hepatic very-low density lipoproteins triglyceride assembly | Jorge Simón | Received |
|
|||
| P04-17 | FAST score for identification of patients with non-alcoholic steatohepatitis (NASH), NAS=4 and significant (F=2) or advanced (F=3) fibrosis | Laura Cantu Sanchez | Received |
|
|||
| P01-18 | In patients with Nonalcoholic Fatty Liver Disease significant fibrosis and the active nonalcoholic steatohepatitis is associated with a moderate-high cardiovascular risk at 10 years. | Paola Casciato | Received |
|
|||
| P03-18 | Differential therapeutic effects of single and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophage biology | Sander Lefere | Received |
|
|||
| P04-18 | Ablation of High mobility group box-1 in intestinal epithelial cells causes intestinal lipid accumulation and reduced non-alcoholic steatohepatitis | Natalia Nieto | Received |
|
|||
| P05-18 | NEDDylation inhibition as a new potential therapy for Non Alcoholic Fatty Liver Disease | Marina Serrano-Macia | Received |
|
|||
| P02-18 | Transcriptomic and epigenetic characterization of a NAFLD murine model | Antonio Gil-Gómez | Received |
|
|||
| P06-18 | Intestinal microbiota and fecal short chain fatty acids in children with non-alcoholic fatty liver disease | Nataliya Zavhorodnia | Received |
|
|||
| P06-19 | PNPLA3 rs738409 Gene Variant Aggravates Kidney Tubular Injury Among NAFLD Population with Persistent Normal Alanine Aminotransferase | Kenneth I. Zheng | Received |
|
|||
| P05-19 | Predictors of high shear wave elastography (SWE) measurements among nonalcoholic fatty liver disease (NAFLD) patients in primary care | Abdel-Aziz Shaheen | Received |
|
|||
| P03-19 | GLI-3 mutation influences weight gain, glucose tolerance and hepatic innate immune populations in a model of non-alcoholic fatty liver disease | Jiawei Li | Received |
|
|||
| P04-19 | Fibrosis impact on quality of life in non-alcoholic fatty liver disease (NAFLD) | Jesus Funuyet-Salas | Received |
|
|||
| P02-19 | Osteopontin deficiency promotes liver senescence mediating the onset of non-alcoholic fatty liver disease during aging | Beatriz Gómez Santos | Received |
|
|||
| P01-19 | Efficacy and Safety of Saroglitazar in Management of NAFLD patients using Transient Elastography: A Single Center Observational Study | Sujit Chaudhuri | Received |
|
|||
| P01-20 | Utility of applying age-adjusted FIB-4 cutoffs in patients with type 2 diabetes | Stefano Ciardullo | Received |
|
|||
| P02-20 | Actions of the protease fibroblast activation protein alpha (FAP) on collagens and FGF21 and roles in chronic liver injury | Mark Gorrell | Received |
|
|||
| P05-20 | Establishment of an novel non-alcoholic steatohepatitis model using a high fat and cholesterol diet in young rabbits | Eiketsu Sho | Received |
|
|||
| P04-20 | Metabolic caracterization of hepatocellular cancer cells related to non-alcoholic fatty liver disease | Claudia Oliveira | Received |
|
|||
| P03-20 | Effect of treatment with dulaglutide on metabolic function and liver tests in patients with NAFLD and diabetes mellitus type 2 | Ekaterina Liusina | Received |
|
|||
| P06-20 | Myeloid Cells-Derived Osteopontin Protects from Diet-Induced Non-alcoholic Fatty Liver Disease in Mice | Natalia Nieto | Received |
|
|||
| P05-21 | Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH | Alicia Meli | Received |
|
|||
| P02-21 | The Vanin 1-Cysteamine pathway regulates immune tolerance upon lipid-induced oxidative stress in non-alcoholic fatty liver disease | Olivier Govaere | Received |
|
|||
| P01-21 | Impact of FAT10 on PPAR-alpha downregulation during NASH progression | Ludivine Clavreul | Received |
|
|||
| P03-21 | Effect of metformin therapy on the clinical and functional state of the liver in patients with metabolic syndrome associated with non-alcoholic fatty liver disease. | Saidrakhim Lukmonov | Received |
|
|||
| P04-21 | Genotyping rs738491 in the SAMM50 Gene May Increase Accuracy of Noninvasive Assessment for Nonalcoholic Steatohepatitis | Kenneth I. Zheng | Received |
|
|||
| P06-21 | Intervention with HE-700 reduces the development of liver inflammation in obese HFD-treated Ldlr-/-.Leiden mice by ameliorating the build-up of hepatic cholesterol | Martine C. Morrison | Received |
|
|||
| P02-22 | Risk stratification of patients with non-alcoholic fatty liver disease in primary care using a reflex testing algorithm of FIB-4 and Enhanced Liver Fibrosis Score | David Harman | Received |
|
|||
| P03-22 | High cholesterol diet and high saturated fatty acid diet: Which is worse for the liver | Makoto Nakamuta | Received |
|
|||
| P01-22 | Similarity of risk factors among individuals with fatty liver with or without harmful alcohol consumption in a healthy population | Helena Cortez-Pinto | Received |
|
|||
| P06-22 | A preclinical study on the effect of an oral edaravone formula on NASH in a rabbit model | Xin-Fu Zhou | Received |
|
|||
| P05-22 | Burden of non alcoholic fatty liver disease in helicobacter pylori infected dyspeptic patients, is it a far reaching implication? | Hafiz Abdul Basit Siddiqui | Received |
|
|||
| P04-22 | results of life style modification on weight loss and factors of failure in nafld | Meryem Oustani | Received |
|
|||
| P04-23 | Suboptimal metabolic control is a risk factor for liver disease progression in patients with type 2 diabetes mellitus | Lucia Parlati | Received |
|
|||
NAFLD SUMMIT 2019
26-28 September 2019 Seville
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 16/09/2019 TO 26/09/2020
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
